Form 4 for URGN UroGen Pharma Ltd.
Accepted 2023-07-28 00:00:00 ET · period of report 2023-07-26 · accession 0001437749-23-021073 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-07-28 | 2023-07-26 | URGN | Cohen Fred E | Dir | A - Grant | $9.54 | +69.3K | 69.3K | New | +$661.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2023-07-26 | A | A | 69,339 | $9.54 | 69,339 | I by Monograph Capital Partners, for which the reporting person is Chair and Chief Investment Officer | — | — | (F1) Represents the reporting person's proportionate interest in shares acquired by entities affiliated with Monograph Capital Partners, for which the reporting person is Chair and Chief Investment Officer |